Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26516685 | 0.90 | MAP4K1 (0.39) | MAP4K1GPR119RAD52LRRK2PTGS2 | |
| SCHEMBL26516688 | 0.90 | MAP4K1 (0.39) | MAP4K1GPR119RAD52LRRK2PTGS2 | |
| SCHEMBL26516738 | 0.89 | PRKDC (0.37) | MAP4K1GPR119PRKDCPTGS2 | |
| SCHEMBL30360618 | 0.89 | PRKDC (0.37) | MAP4K1GPR119PRKDCPTGS2 | |
| SCHEMBL30360601 | 0.85 | MAP4K1 (0.47) | MAP4K1GPR119RAD52LRRK2PIK3CA | |
| SCHEMBL26516557 | 0.85 | MAP4K1 (0.47) | MAP4K1GPR119RAD52LRRK2PIK3CA | |
| SCHEMBL29006623 | 0.82 | MAP4K1 (0.41) | MAP4K1GPR119RAD52LRRK2 | |
| SCHEMBL30360600 | 0.82 | HRH3 (0.45) | MAP4K1GPR119RAD52LRRK2PRKDC | |
| SCHEMBL26516674 | 0.82 | MAP4K1 (0.41) | MAP4K1GPR119RAD52LRRK2 | |
| SCHEMBL26516668 | 0.82 | HRH3 (0.45) | MAP4K1GPR119RAD52LRRK2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | claimed |
| EP-4200015-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2023-06-28 | — | — | EP | claimed |
| CN-115956077-A | Substituted heteroaryl compounds as TLR9 inhibitors | 百时美施贵宝公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | MAP4K1 2619/4885GPR119 163/4885RAD52 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.